Hosted on MSN1mon
Disc raises $225.5m as it eyes approval of rare skin disorder drugThe therapy targets erythropoietic protoporphyria (EPP), a rare genetic disorder that ... Patients who opted to continue into an open-label extension study for another 24 weeks demonstrated ...
Disc is also running a 26-subject open-label phase 2 study of bitopertin in patients with EPP and XLP, called BEACON, which was reported at last year's American Society of Haematology (ASH ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results